[A21-143] Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2022
Project no.:
A21-143
Commission:
Commission awarded on 15.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adolescents aged 12 to < 18 years who weigh at least 30 kg with chronic hepatitis C (genotypes 1 or 4)
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-75 | Elbasvir/grazoprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V | Commission completed |